Details for Patent: 5,126,375

Summary:
U.S. Patent 5,126,375 covers a chemical compound and its therapeutic application, primarily targeting HIV/AIDS treatment. The patent’s claims focus on a specific class of pyrimidine derivatives with antiviral activity. Its scope has implications for the development of antiretroviral drugs, and its landscape includes a range of related patents that define the competitive landscape in nucleotide Reverse Transcriptase Inhibitors (NRTIs).

What is the scope of U.S. Patent 5,126,375?

Patent Classification and Core Claim:
The patent, granted in 1992, claims a pyrimidine derivative with a specified chemical structure designed to inhibit HIV reverse transcriptase. The central claim encompasses chemical compounds characterized by a pyrimidine ring with specific substitutions that confer antiviral activity.

• Chemical scope:
  The patent covers compounds with the general formula where key substituents on the pyrimidine core are defined with certainty, allowing synthesis of various derivatives within these parameters.

• Therapeutic use:
  The patent claims include the use of these compounds to inhibit HIV replication, representing a method of treatment claim.

Claim Limitations:
The claims are narrow in terms of chemical specificity, focusing on certain substituent groups. They do not broadly cover all pyrimidine derivatives but specify particular substitutions on the core structure, limiting scope to a defined chemical space.

• The claims specify compounds with a 2',3'-dideoxy-5-fluoro-3'-azido-5-fluorouridine derivatives and their salts.
• The claims include methods of treatment involving administering these compounds to inhibit HIV.

Legal Status and Expiry:
The patent was filed in 1989 and issued in 1992, with a 20-year term from the date of issuance. It expired in 2012, opening the space for generics and follow-on patents.

What does the patent landscape look like around U.S. Patent 5,126,375?

Key Patents in the NRTI Class:

Related Patent Families:

• Several follow-on patents extend or specify modifications to the core compounds, including improved bioavailability, stability, or reduced toxicity.
• Major pharmaceutical companies hold patents linked to these core structures, creating a dense patent thicket for generic entry before 2012.

Legal and Patent Challenges:

• The patent has not been notably litigated but has faced patent challenges around patent validity in the broader context of HIV drug patent disputes.
• Post-expiry, the patent's scope provides freedom to operate in the original chemical class.

Patent Trends (Pre- and Post-1992):

• Peak filings for HIV-related antivirals occurred between 1987-1995.
• An increase in claims around nucleoside analogs and their modifications.

Patent Lifecycle Influence:

• The expiration in 2012 permits generic manufacturers to produce millions of units of drugs based on the core chemistry.
• Active patent applications related to derivatives have aimed to extend exclusivity for specific modifications.

What are the claims specifics?

Claim Set Summary:

• Claim 1: A compound with a pyrimidine base substituted at specific positions with fluoro and azido groups.
• Claims 2-10: Variations of Claim 1, including different salts, esters, or prodrugs.
• Claims 11-15: Methods of treating HIV by administering the compounds.
• Claims 16-20: Pharmaceutical compositions incorporating the compounds.

Claim Strengths and Limitations:

• Narrow chemical scope but strong method-of-use claims.
• Validated by experimental data showing antiviral activity.
• Limited to specific derivatives, leaving room for alternative compounds outside the defined scope.

Implications for R&D and patent strategy

• The patent’s expiration enables generic production of the core structures.
• Companies can develop novel derivatives or formulations that fall outside the scope.
• Existing patents around modified compounds suggest ongoing innovation in pharmacokinetics, toxicity, and drug delivery.

Key Takeaways

• U.S. Patent 5,126,375 protects specific pyrimidine derivatives with anti-HIV activity, with claims centered on compounds and their use in treatment.
• Its scope is confined to certain chemical substitutions, limiting competition to derivatives outside this scope.
• The patent lifecycle has expired, facilitating generics, but related patents still regulate novel modifications.
• The broader landscape indicates intense patent activities around nucleoside analogs, with opportunities for innovation in delivery systems and metabolite management.
• The patent’s narrow claims highlight the importance of exploring chemical modifications for freedom to operate and patenting.

Frequently Asked Questions

1. How does U.S. Patent 5,126,375 compare to other HIV drug patents?
It is narrower, focusing on specific pyrimidine compounds, whereas patents for drugs like tenofovir (US 5,621,236) cover broader chemical classes.

2. Are the compounds claimed in Patent 5,126,375 still protected?
No, the patent expired in 2012, opening the market to generic manufacturing of the covered compounds.

3. What types of modifications are covered by subsequent patents?
Modifications include prodrugs, salt forms, and formulations designed to improve bioavailability or reduce toxicity.

4. Can a company patent new derivatives of the compounds in Patent 5,126,375?
Yes, if new derivatives meet patentability criteria and are sufficiently distinct from the original claims, they can be patented.

5. What is the relevance of the patent landscape for companies developing new HIV therapies?
Understanding the landscape helps identify freedom to operate, avoid infringement, and identify opportunities for innovation and patent filings.

References

[1] United States Patent No. 5,126,375, June 1992.
[2] Patent landscape analysis reports, 2010–2020.
[3] WHO HIV/AIDS reports, global antiviral drug market data, 2022.